Department of Woman and Baby, University Medical Centre Utrecht, The Netherlands.
Int J Womens Health. 2010 Aug 9;2:137-42. doi: 10.2147/ijwh.s7219.
Preterm birth is strongly associated with neonatal death and long-term neurological morbidity. The purpose of tocolytic drug administration is to postpone threatening preterm delivery for 48 hours to allow maximal effect of antenatal corticosteroids and maternal transportation to a center with specialized neonatal care facilities. There is uncertainty about the value of atosiban (oxytocin receptor antagonist) and nifedipine (calcium channel blocker) as first-line tocolytic drugs in the management of preterm labor. For nifedipine, concerns have been raised about unproven safety, lack of placebo-controlled trials, and its off-label use. The tocolytic efficacy of atosiban has also been questioned because of a lack of reduction in neonatal morbidity. This review discusses the available evidence, the pros and cons of either drug and aims to provide information to support a balanced choice of first-line tocolytic drug: atosiban or nifedipine?
早产与新生儿死亡和长期神经发育障碍密切相关。使用宫缩抑制剂的目的是将即将发生的早产推迟 48 小时,以便最大程度地发挥产前皮质激素的作用,并将产妇转运至具有专业新生儿护理设施的中心。阿托西班(催产素受体拮抗剂)和硝苯地平(钙通道阻滞剂)作为治疗早产的一线宫缩抑制剂的价值存在不确定性。对于硝苯地平,人们对其未经证实的安全性、缺乏安慰剂对照试验以及其超适应证使用表示担忧。由于阿托西班未能降低新生儿发病率,其保胎效果也受到质疑。本文讨论了现有的证据,对这两种药物的优缺点进行了分析,并旨在提供信息以支持一线宫缩抑制剂(阿托西班或硝苯地平)的选择。